Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00045292 · ClinicalTrials.gov registry record · Phase 3
Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation
A Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
- Completed
- Registry status
- Phase 3
- Development phase
NCT00045292: Completed Phase 3 study, sponsored by Fred Hutchinson Cancer Center.
NCT00045292 is a Phase 3 study that has completed, run by Fred Hutchinson Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00045292, a Phase 3 study, has completed, sponsored by Fred Hutchinson Cancer Center.
- COMPLETED
- Registry status
- Phase 3
- Development phase
Study Summary
RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the effectiveness of valacyclovir in preventing cytomegalovirus in patients who are undergoing donor stem cell transplantation.
Interventions
- DRUG valacyclovir
- DRUG acyclovir
- DRUG acyclovir sodium
Trial Details
| Field | Value |
|---|---|
| Start Date | 2002-04 |
| Est. Completion | 2004-10 |
| Phase | Phase 3 |
What the finished NCT00045292 record still lists
NCT00045292 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 3 interventions - of which valacyclovir is the first listed.
NCT00045292 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00045292 about?
NCT00045292 is a clinical study titled "Valacyclovir in Preventing Cytomegalovirus Infection in Patients Who Are Undergoing Donor Stem Cell Transplantation". RATIONALE: Antivirals such as valacyclovir act against viruses and may be effective in preventing cytomegalovirus. It is not yet known if valacyclovir is effective in preventing cytomegalovirus in patients undergoing stem cell transplantation. PURPOSE: Randomized phase III trial to determine the ef...
What is the current status of trial NCT00045292?
This trial is currently completed. It is a Phase 3 study. The study started on 2002-04. Estimated completion is 2004-10.
What interventions are being tested in trial NCT00045292?
The interventions under investigation include: valacyclovir (DRUG), acyclovir (DRUG), acyclovir sodium (DRUG).
Who is sponsoring clinical trial NCT00045292?
This trial is sponsored by Fred Hutchinson Cancer Center, which has 483 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia